CD19-targeted chimeric antigen receptor (CD19 CAR) T cells have efficacy for relapsed/refractory B-cell malignancies, but relapses occur in a high percentage of
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have
Key Points. Using whole-genome sequencing and RNA-seq, we characterized the genomic landscape of 295 DS-ALL cases and identified 15 distinct subtypes.DS-ALL exh
Children with Down syndrome (DS) have a 20 times higher risk of developing acute lymphoblastic leukemia (DS-ALL). In this issue of Blood, Li et al1 report…
Key Points. Non-Restrictive diet is non-inferior to traditional Protective diet during neutropenia after HSCT.In multivariable analysis, multiple myeloma diagno
Key Points. Non-Restrictive diet is non-inferior to traditional Protective diet during neutropenia after HSCT.In multivariable analysis, multiple myeloma diagno
Key Points. Non-Restrictive diet is non-inferior to traditional Protective diet during neutropenia after HSCT.In multivariable analysis, multiple myeloma diagno
